Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Wirth M. ; Tyrrell C. ; Delaere K. ; Sanchez-Chapado M. ; Ramon J. ; Wallace D.M.A. ; Hetherington J. ; Pina F. ; Heyns C.F. ; Navani S. ; Armstrong J. (2007)


Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: